KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) EBT: 2019-2024

Historic EBT for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to -$464.8 million.

  • Recursion Pharmaceuticals' EBT fell 69.58% to -$162.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$715.7 million, marking a year-over-year decrease of 86.89%. This contributed to the annual value of -$464.8 million for FY2024, which is 39.94% down from last year.
  • Per Recursion Pharmaceuticals' latest filing, its EBT stood at -$464.8 million for FY2024, which was down 39.94% from -$332.1 million recorded in FY2023.
  • Over the past 5 years, Recursion Pharmaceuticals' EBT peaked at -$84.6 million during FY2020, and registered a low of -$464.8 million during FY2024.
  • For the 3-year period, Recursion Pharmaceuticals' EBT averaged around -$345.5 million, with its median value being -$332.1 million (2023).
  • Data for Recursion Pharmaceuticals' EBT shows a maximum YoY tumbled of 120.39% (in 2021) over the last 5 years.
  • Over the past 5 years, Recursion Pharmaceuticals' EBT (Yearly) stood at -$84.6 million in 2020, then plummeted by 120.39% to -$186.5 million in 2021, then dropped by 28.42% to -$239.5 million in 2022, then slumped by 38.69% to -$332.1 million in 2023, then plummeted by 39.94% to -$464.8 million in 2024.